Spots Global Cancer Trial Database for Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial
Official Title: Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial
Study ID: NCT01341756
Conditions
Interventions
Study Description
Brief Summary: The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls.
Detailed Description: The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls. (Tey et al.) With this dose fractionation is used for bleeding, there is an increase in response rates from 55%(historical) to 75%for pain, there is an increase in response rates from 25% (historical) to 45% for obstruction, there is an increase in response rates from 25% (historical) to 45%
Eligibility
Minimum Age: 21 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National University Hospital, Singapore, , Singapore
Contact Details
Name: Jeremy Tey, FRANZCR
Affiliation: National University Hospital, Singapore
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
